Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seer Inc SEER

Technology Scientific & Technical Instruments
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution... see more

Recent & Breaking News (NDAQ:SEER)

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)

GlobeNewswire 4 days ago

Seer to Participate in Upcoming November Investor Conferences

GlobeNewswire November 8, 2024

Seer Reports Third Quarter 2024 Financial Results

GlobeNewswire November 6, 2024

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

GlobeNewswire November 6, 2024

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024

GlobeNewswire October 31, 2024

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024

GlobeNewswire October 21, 2024

Seer to Report Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire October 17, 2024

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire August 22, 2024

Seer Appoints Nicolas Roelofs to its Board of Directors

GlobeNewswire August 14, 2024

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire August 9, 2024

Seer Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire July 18, 2024

Seer Proteograph(TM) Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

GlobeNewswire June 11, 2024

Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study

GlobeNewswire June 2, 2024

Seer Reports First Quarter 2024 Financial Results

GlobeNewswire May 8, 2024

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

GlobeNewswire May 8, 2024

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

GlobeNewswire April 23, 2024

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

GlobeNewswire February 29, 2024

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 21, 2024

Seer Proteograph(TM) Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

GlobeNewswire February 6, 2024